There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. In addition, the 100‑mg tablet contains FD&C Blue No. The patient should be monitored for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first.
Bupropion does not inhibit monoamine oxidase.Bupropion is a racemic mixture. False-positive test results may result even following discontinuation of bupropion therapy. In addition, there have been rare, spontaneous postmarketing reports of erythema multiforme, Stevens‑Johnson syndrome, and anaphylactic shock associated with bupropion. However, higher doses (which could not be tested because of the risk of seizure) might be modestly attractive to those who abuse CNS stimulant drugs.Wellbutrin SR is intended for oral use only. Use caution when administering Wellbutrin SR concomitantly with these drugs.In postmarketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with Wellbutrin SR. or elimination may be expected to influence the degree and extent of accumulation of the active metabolites of bupropion. The first section is about the risk of suicidal thoughts and actions with antidepressant medicines; the second section is about the risk of changes in thinking and behavior, depression and suicidal thoughts or actions with medicines used to quit smoking; and the third section is entitled “What Other Important Information Should I Know About WELLBUTRIN SR?”Antidepressant Medicines, Depression and Other Serious Mental Illnesses, and Suicidal Thoughts or ActionsWhat is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions?Antidepressant medicines may increase the risk of suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment.Depression or other serious mental illnesses are the most important causes of suicidal thoughts and actions. Instruct patients to contact a healthcare professional if such reactions occur.The pupillary dilation that occurs following use of many antidepressant drugs including Wellbutrin SR may trigger an angle-closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.Anaphylactoid/anaphylactic reactions have occurred during clinical trials with bupropion. If weight loss is a major presenting sign of a patient’s depressive illness, the anorectic and/or weight‑reducing potential of WELLBUTRIN SR should be considered.The following adverse reactions have been identified during post-approval use of Wellbutrin SR and are not described elsewhere in the label. Adverse reactions have included restlessness, agitation, tremor, ataxia, gait disturbance, vertigo, and dizziness. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed hypersensitivity. The extent of protein binding of the hydroxybupropion metabolite is similar to that for bupropion; whereas, the extent of protein binding of the threohydrobupropion metabolite is about half that seen with bupropion.Bupropion is extensively metabolized in humans. Tell your doctor if your condition does not improve or if it worsens.An empty tablet shell may appear in your stool. Advise patients to minimize or avoid use of alcohol.As the dose is increased during initial titration to doses above 150 mg/day, instruct patients to take WELLBUTRIN SR in 2 divided doses, preferably with at least 8 hours between successive doses, to minimize the risk of seizures.Patients should be advised that taking Wellbutrin SR can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure glaucoma. Seizures and/or cases of death have been reported when bupropion has been administered intranasally or by parenteral injection.Studies in rodents and primates demonstrated that bupropion exhibits some pharmacologic actions common to psychostimulants. Call 1-800-222-1222 or refer to www.poison.org.There are no known antidotes for bupropion. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide and is printed with edible black ink. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.Although Wellbutrin SR is not indicated for smoking cessation treatment, it contains the same active ingredient as ZYBAN which is approved for this use. There should be an interval of at least 8 hours between successive doses. The pharmacological activity and pharmacokinetics of the individual enantiomers have not been studied. 40 Lake, and the 200‑mg tablet contains FD&C Red No.
It is important for you to follow-up with your healthcare provider until your symptoms go away. At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of treatment with Wellbutrin SR. Conversely, at least 14 days should be allowed after stopping Wellbutrin SR before starting an MAOI antidepressant False-positive urine immunoassay screening tests for amphetamines have been reported in patients taking bupropion. The risk of hypertension is increased if Wellbutrin SR is used concomitantly with MAOIs or other drugs that increase dopaminergic or noradrenergic activity Data from a comparative trial of the sustained-release formulation of bupropion HCl, nicotine transdermal system (NTS), the combination of sustained-release bupropion plus NTS, and placebo as an aid to smoking cessation suggest a higher incidence of treatment-emergent hypertension in patients treated with the combination of sustained-release bupropion and NTS.
Bupropion does not inhibit monoamine oxidase.Bupropion is a racemic mixture. False-positive test results may result even following discontinuation of bupropion therapy. In addition, there have been rare, spontaneous postmarketing reports of erythema multiforme, Stevens‑Johnson syndrome, and anaphylactic shock associated with bupropion. However, higher doses (which could not be tested because of the risk of seizure) might be modestly attractive to those who abuse CNS stimulant drugs.Wellbutrin SR is intended for oral use only. Use caution when administering Wellbutrin SR concomitantly with these drugs.In postmarketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with Wellbutrin SR. or elimination may be expected to influence the degree and extent of accumulation of the active metabolites of bupropion. The first section is about the risk of suicidal thoughts and actions with antidepressant medicines; the second section is about the risk of changes in thinking and behavior, depression and suicidal thoughts or actions with medicines used to quit smoking; and the third section is entitled “What Other Important Information Should I Know About WELLBUTRIN SR?”Antidepressant Medicines, Depression and Other Serious Mental Illnesses, and Suicidal Thoughts or ActionsWhat is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions?Antidepressant medicines may increase the risk of suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment.Depression or other serious mental illnesses are the most important causes of suicidal thoughts and actions. Instruct patients to contact a healthcare professional if such reactions occur.The pupillary dilation that occurs following use of many antidepressant drugs including Wellbutrin SR may trigger an angle-closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.Anaphylactoid/anaphylactic reactions have occurred during clinical trials with bupropion. If weight loss is a major presenting sign of a patient’s depressive illness, the anorectic and/or weight‑reducing potential of WELLBUTRIN SR should be considered.The following adverse reactions have been identified during post-approval use of Wellbutrin SR and are not described elsewhere in the label. Adverse reactions have included restlessness, agitation, tremor, ataxia, gait disturbance, vertigo, and dizziness. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed hypersensitivity. The extent of protein binding of the hydroxybupropion metabolite is similar to that for bupropion; whereas, the extent of protein binding of the threohydrobupropion metabolite is about half that seen with bupropion.Bupropion is extensively metabolized in humans. Tell your doctor if your condition does not improve or if it worsens.An empty tablet shell may appear in your stool. Advise patients to minimize or avoid use of alcohol.As the dose is increased during initial titration to doses above 150 mg/day, instruct patients to take WELLBUTRIN SR in 2 divided doses, preferably with at least 8 hours between successive doses, to minimize the risk of seizures.Patients should be advised that taking Wellbutrin SR can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure glaucoma. Seizures and/or cases of death have been reported when bupropion has been administered intranasally or by parenteral injection.Studies in rodents and primates demonstrated that bupropion exhibits some pharmacologic actions common to psychostimulants. Call 1-800-222-1222 or refer to www.poison.org.There are no known antidotes for bupropion. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide and is printed with edible black ink. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.Although Wellbutrin SR is not indicated for smoking cessation treatment, it contains the same active ingredient as ZYBAN which is approved for this use. There should be an interval of at least 8 hours between successive doses. The pharmacological activity and pharmacokinetics of the individual enantiomers have not been studied. 40 Lake, and the 200‑mg tablet contains FD&C Red No.
It is important for you to follow-up with your healthcare provider until your symptoms go away. At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of treatment with Wellbutrin SR. Conversely, at least 14 days should be allowed after stopping Wellbutrin SR before starting an MAOI antidepressant False-positive urine immunoassay screening tests for amphetamines have been reported in patients taking bupropion. The risk of hypertension is increased if Wellbutrin SR is used concomitantly with MAOIs or other drugs that increase dopaminergic or noradrenergic activity Data from a comparative trial of the sustained-release formulation of bupropion HCl, nicotine transdermal system (NTS), the combination of sustained-release bupropion plus NTS, and placebo as an aid to smoking cessation suggest a higher incidence of treatment-emergent hypertension in patients treated with the combination of sustained-release bupropion and NTS.